NEW YORK, NY -- June 17, 2015 -- InvestorsHub NewsWire -- Small Cap Profit makes the connection between sophisticated investors and high quality micro and small cap companies that are currently undervalued. We are an issuer of reports written by experienced financial analysts and who provide a straight forward assessment of a profiled company. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

*Special Analyst Profile*        

Tel-Instrument Electronics Corp. (NYSE-MKT: TIK) Company Highlights:

  • -Analyst gives 100% price target from current price.

    -Strong competitive position in next generation Mode 5 flight-line test sets. Mode 5 is the next generation of the IFF (Identification Friend or Foe) system used by the Air Traffic Control System to identify and track military aircraft.

    -Significant regulatory, IP, and financial barriers to entry in core markets.

    -Multi-year projected revenue and profit growth driven by roll out of Mode 5 products.

    -$33 million in shippable backlog as of December 31, 2014, with large amount of expected follow – on sole  source orders.

    -Diverse customer base with long-term relationships.

An analyst report on TIK that includes a brief company overview, technology solutions, financial review, analyst summary, valuation, and recommendation can be viewed by using the following link at no cost and no email entry.

http://bit.ly/__TIK_AnalystReport

Or if you would like to receive profiles quicker you can text "Profits" to 25827

4 Brief Reports:

Capstone Turbine Corp. (NASDAQ: CPST) is a producer of low-emission microturbine systems. Capstone Turbine has shipped over 8,500 Capstone Microturbine systems to customers worldwide. The company's systems have logged millions of documented runtime operating hours. Capstone Turbine is a member of the U.S. Environmental Protection Agency's Combined Heat and Power Partnership.

CPST has released its fourth quarter and year-end financial results. You can read a full summary in the report located at this link: http://bit.ly/_CPST_AnalystBrief

Galena Biopharma, Inc. (NASDAQ: GALE) is a biopharmaceutical company developing and commercializing, targeted oncology therapeutics across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax™ (nelipepimut-S) currently in an international, Phase 3 clinical trial.

Analyst brief can be found here: http://bit.ly/_GALE_AnalystBrief

Apple, Inc. (NASDAQ: AAPL) designs, manufactures, and markets mobile communication and media devices, personal computers, watches, and portable digital music players worldwide.

Apple Pay has kicked off a new era in online payments and there are a plethora of articles on the subject. Read AAPL’s comments on their growing payment application in the report that follows: http://bit.ly/_AAPL_AnalystBrief

22nd Century Group, Inc. (NYSE MKT: XXII) is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants through genetic engineering and plant breeding. 22nd Century owns or exclusively controls 128 issued patents and 52 pending patent applications in 96 countries.

XXII has obtained licensing in New York giving them the ability to distribute product throughout the state. Read about the new licenses as well as information about a completed, direct stock offering in this report: http://bit.ly/_XXII__AnalystBrief

Forward-Looking Disclaimer   
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.    

Compliance Procedure   
Content is researched, written and reviewed on a best-effort basis by a 3rd party research analyst. However, we are only human and may make mistakes. This report was prepared for informational purposes only.  A full disclaimer can be found by viewing the full analyst report. We do not engage in high frequency trading or hold any positions of profiled company.
For more information and services provided beyond this release please use contact information provided below. If you notice any errors or omissions, please notify us below.

If you wish to have a company covered in more detail by our team, or wish to learn more about our services, please contact us at editor@smallcapprofit.com. For any urgent concerns or inquiries please contact us.

Source: Small Cap Profit
Contact: editor@smallcapprofit.com
 

SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more SELLAS Life Sciences Charts.
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more SELLAS Life Sciences Charts.